Clinical trials in autism spectrum disorder: evidence, challenges and future directions
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Purpose of review: The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions Recent findings: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin). However, there is no evidence yet to support the routine use of pharmaceuticals for the treatment of core symptom domains. Challenges in the field include biological heterogeneity within ASD, lack of biomarkers that clarify biological heterogeneity or predict response to treatment, lack of data across the lifespan, and suboptimal outcome measures. Summary: Several compounds have evidence for the treatment of co-occurring symptoms in children and youth with ASD, although pharmacological interventions for core symptoms are still lacking. Identifying the various biologies underling ASD and developing biomarkers that stratify biologically homogeneous populations are both necessary to realize the promise of precision medicine in ASD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model of autism: increased ratio of excitation/inhibition in key neural systems
Rubenstein, J. L. R., & Merzenich, M. M. (2003) · Genes, Brain and Behavior · doi:10.1034/j.1601-183x.2003.00037.x · Cited by 2,768
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Self-citationMelatonin in autism spectrum disorders: a systematic review and meta-analysis
ROSSIGNOL, D. A., & FRYE, R. E. (2011) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2011.03980.x · Cited by 468
Aman, M. G., Mcdougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Stigler, K. A., Bearss, K., Butter, E., Swiezy, N. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181bfd669 · Cited by 371
Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., Wang, A. T., Pepa, L., Tanel, N., Kushki, A., et al. (2012) · Molecular Autism · doi:10.1186/2040-2392-3-16 · Cited by 350
Self-citationIntranasal oxytocin treatment for social deficits and biomarkers of response in children with autism
Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., Summers, J. E., Hinman, K. E., Motonaga, K. S., Phillips, J. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705521114 · Cited by 349
Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.162 · Cited by 344
Clonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder
JASELSKIS, C. A., COOK, E. H., FLETCHER, K. E., & LEVENTHAL, B. L. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199210000-00005 · Cited by 328
Cited by
Lai, M.-C., Anagnostou, E., Wiznitzer, M., Allison, C., & Baron-Cohen, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30034-x · Cited by 250
Self-citationJuarez-Martinez, E. L., Sprengers, J. J., Cristian, G., Oranje, B., van Andel, D. M., Avramiea, A.-E., Simpraga, S., Houtman, S. J., Hardstone, R., Gerver, C., et al. (2023) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.08.009 · Cited by 48
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- Anagnostou, E.
- Venue
- Current Opinion in Neurology
- Published
- 2018-04
- Volume
- 31
- Issue
- 2
- Pages
- 119-125
- ISSN
- 1350-7540 (ISSN-L)
- 1473-6551
- OpenAlex
- W2790722175
- Cited by
- 72
- References
- 27
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical trials in autism spectrum disorder: evidence, challenges and future directions. https://app.cochat.ai/papers/10.1097/wco.0000000000000542
- The paper
- Anagnostou, E. (2018). Clinical trials in autism spectrum disorder: evidence, challenges and future directions. Current Opinion in Neurology. https://doi.org/10.1097/wco.0000000000000542
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.